接受放射免疫治疗滤泡性淋巴瘤患者的组织学转化及治疗相关骨髓增生异常/急性髓系白血病风险
单中心研究分析115例1987-2012年接受钇-90替伊莫单抗放射免疫治疗的滤泡性淋巴瘤患者,28%(n=32)发生组织学转化,中位距诊断60个月、距放射免疫治疗20个月;既往氟达拉滨治疗者组织学转化风险显著更高(10年风险67% vs 26%,P=0.015);8%(9/115)发生治疗相关骨髓增生异常/急性髓系白血病,中位41.4个月。
要点
- 放射免疫治疗后28%(32/115)发生组织学转化,中位距诊断60个月、距治疗20个月。
- 既往氟达拉滨者组织学转化10年风险67%,无氟达拉滨者26%(P=0.015)。
- 治疗相关髓系肿瘤风险8%(9/115),无氟达拉滨者10年13%,氟达拉滨者29%。
核心结论
- 未暴露氟达拉滨的滤泡性淋巴瘤患者10年组织学转化总体风险似乎与文献中未接受放射免疫治疗者相似。
- 既往嘌呤类似物治疗的患者组织学转化风险显著更高。
研究设计与样本
- 单中心研究分析1987-2012年间连续接受钇-90替伊莫单抗放射免疫治疗的115例滤泡性淋巴瘤患者。
- 111例(97%)因进展期滤泡性淋巴瘤接受放射免疫治疗,其余4例作为一线治疗。
主要发现
- 28%(n=32)发生组织学转化,中位距诊断60个月、距放射免疫治疗20个月。
- 接受氟达拉滨的25例中48%(12/25)发生组织学转化。
- 氟达拉滨组与无氟达拉滨组组织学转化10年风险分别为67%与26%(P=0.015)。
- 仅既往氟达拉滨与放射免疫治疗后组织学转化风险显著相关。
- 8%(9/115)发生治疗相关骨髓增生异常综合征/急性髓系白血病,中位41.4个月(范围5-89);无氟达拉滨组(n=90)与氟达拉滨组(n=25)10年风险分别为13%与29%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Histological transformation (HT) of follicular lymphoma (FL) to an aggressive lymphoma after chemotherapy remains a key issue. The incidence of HT after radioimmunotherapy (RIT) is unknown. This single institution study analysed the risk of HT in FL after treatment with yttrium-90 ibritumomab tiuxetan in 115 consecutive patients treated during 1987-2012. RIT was administered for progressive FL in 111 (97%) patients and as first-line therapy in the remaining 4. 28% (n = 32) had HT, occurring at a median of 60 months from diagnosis and 20 months after RIT. 48% (12/25) of patients who received fludarabine developed HT. The estimated 10-year risk of HT in the fludarabine and non-fludarabine groups was 67% and 26% respectively (P = 0·015). Only prior fludarabine was significantly associated with predicting the risk of HT after RIT. 8% (9/115) of patients developed therapy-related myelodysplastic syndrome/acute myeloid leukaemia (tMDS/AML) at a median of 41·4 months (range, 5-89). The estimated 10-year risk of tMDS/AML in non-fludarabine treated patients (n = 90) versus fludarabine treated (n = 25) was 13% and 29%, respectively. The estimated overall risk of FL undergoing HT at 10 years without fludarabine exposure appears similar to patients reported in the literature that have not received RIT. Patients with prior purine-analogue therapy are at significantly higher risk of HT.
引用
- Epperla N, Pham AQ, Burnette BL, et al. Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. Br J Haematol. 2017. PMID: 28466487. doi:10.1111/bjh.14688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。